Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator.
作者信息
Berg D T, Grinnell B W
机构信息
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285.
出版信息
Protein Sci. 1993 Jan;2(1):126-7. doi: 10.1002/pro.5560020114.
Abstract
摘要
相似文献
1
Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator.沉默糖基化位点中的脯氨酸突变为甘氨酸（P219G）导致组织型纤溶酶原激活剂完全糖基化。
Protein Sci. 1993 Jan;2(1):126-7. doi: 10.1002/pro.5560020114.
2
Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.
J Cell Biochem. 1999 Dec 1;75(3):446-61.
3
rtPA is a well-characterized protein.
Dev Biol Stand. 1998;96:113-21.
4
Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment.
Biotechnol Ther. 1989;1(3):273-304.
5
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.组织型纤溶酶原激活物的可变区-1通过促进催化作用赋予纤溶酶原激活物抑制剂-1对凝血酶的特异性：由异源蛋白质表面环解除动力学阻滞。
J Mol Biol. 1999 Oct 29;293(3):613-27. doi: 10.1006/jmbi.1999.3178.
6
Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.纤溶酶原激活物抑制剂-1的底物行为与反应位点环插入缺失无关。
Biochemistry. 1996 Jun 11;35(23):7474-81. doi: 10.1021/bi960079d.
7
Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.凝血酶与纤溶酶原激活物抑制剂-1反应缓慢的结构基础解析。
Biochemistry. 1998 Sep 22;37(38):13138-42. doi: 10.1021/bi9808518.
8
The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.重组双链人组织型纤溶酶原激活剂催化结构域的2.3埃晶体结构。
J Mol Biol. 1996 Apr 26;258(1):117-35. doi: 10.1006/jmbi.1996.0238.
9
Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.纤溶酶原激活物抑制剂-1与其靶蛋白酶之间复合物形成的合理设计。
J Struct Biol. 1997 Apr;118(3):236-42. doi: 10.1006/jsbi.1997.3860.
10
A general method for the identification of regions suitable for site-directed silent mutagenesis.
Biotechniques. 1992 Mar;12(3):382-4.
引用本文的文献
1
Substitution of asparagine residues in Aspergillus awamori glucoamylase by site-directed mutagenesis to eliminate N-glycosylation and inactivation by deamidation.通过定点诱变替换泡盛曲霉糖化酶中的天冬酰胺残基，以消除N-糖基化和脱酰胺导致的失活。
Biochem J. 1994 Jul 1;301 ( Pt 1)(Pt 1):275-81. doi: 10.1042/bj3010275.
本文引用的文献
1
Amino acid sequence of the heavy chain of bovine protein C.牛蛋白C重链的氨基酸序列。
J Biol Chem. 1982 Oct 25;257(20):12180-90.
2
Functional properties of carbohydrate-depleted tissue plasminogen activator.
Biochemistry. 1984 Dec 4;23(25):6191-5. doi: 10.1021/bi00320a046.
3
The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins.糖蛋白中碳水化合物 - 肽键的性质与代谢。
Biochem Soc Symp. 1974(40):17-26.
4
Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F.肽：N-糖苷酶F对天冬酰胺连接聚糖的去糖基化作用
Biochemistry. 1985 Aug 13;24(17):4665-71. doi: 10.1021/bi00338a028.
5
Rapid and efficient site-specific mutagenesis without phenotypic selection.无需表型筛选的快速高效位点特异性诱变。
Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92. doi: 10.1073/pnas.82.2.488.
6
Amino acid sequence of human von Willebrand factor.人血管性血友病因子的氨基酸序列。
Biochemistry. 1986 Jun 3;25(11):3171-84. doi: 10.1021/bi00359a015.
7
Rapid and efficient site-specific mutagenesis without phenotypic selection.无需表型选择的快速高效位点特异性诱变。
Methods Enzymol. 1987;154:367-82. doi: 10.1016/0076-6879(87)54085-x.
8
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.组织型纤溶酶原激活剂。其药理学及作为溶栓剂的治疗用途综述。
Drugs. 1989 Sep;38(3):346-88. doi: 10.2165/00003495-198938030-00003.
9
Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.纤维蛋白特异性在治疗性溶栓中的重要性以及使用组织型纤溶酶原激活剂和尿激酶原的序贯与协同组合的原理。
Semin Thromb Hemost. 1989 Apr;15(2):123-8. doi: 10.1055/s-2007-1002694.
10
Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain.
J Biol Chem. 1990 Mar 25;265(9):5170-7.
Zotero 插件